Immutep Limited ADR Dossier
Qualitative Analysis
Business overview
Immutep Ltd (ASX: IMM, NASDAQ: IMMP) is a late clinical-stage biotechnology company pioneering the development of novel immunotherapies for cancer and autoimmune diseases. The company is a global leader in Lymphocyte Activation Gene-3 (LAG-3) related therapeutics, which play a vital role in regulating the human immune system. Immutep's diversified product portfolio harnesses LAG-3's ability to stimulate the immune response to fight cancer (via its lead candidate, eftilagimod alpha, or "efti") or modulate it to combat autoimmune diseases (via IMP761). Efti is a first-in-class soluble LAG-3 protein and antigen-presenting cell (APC) activator currently being evaluated in registrational Phase III trials.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Initiation of cost-reduction measures following the discontinuation of the TACTI-004 Phase III trial. This includes winding down trial activities, targeted headcount reductions, and other operating expense cuts to preserve capital.
Expected impact: Extends the company's cash runway from Q2 CY2027 into H1 CY2028, preserving its A$110.6 million cash balance (as of March 31, 2026) to fund earlier-stage pipeline assets.
Advancing the first-in-class LAG-3 agonist antibody, IMP761, through early-stage clinical development for autoimmune diseases.
Expected impact: Demonstrating safety and target engagement in Phase I to support progression to Phase II trials and potentially secure a global development partner.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Grants Dr. Reddy's exclusive rights to develop and commercialize eftilagimod alfa (efti) in emerging markets (including India, Southeast Asia, and Latin America), validating the drug's commercial potential and providing non-dilutive funding.
Terms: Upfront payment of USD 20 million (received January 2026), eligibility for up to USD 349.5 million in development, regulatory, and commercial milestones, plus double-digit royalties on sales. Immutep retains global manufacturing rights.
Collaborative clinical trials evaluating eftilagimod alfa (efti) in combination with MSD's anti-PD-1 therapy KEYTRUDA (pembrolizumab) across multiple oncology indications.
Terms: MSD supplies KEYTRUDA for the trials, while Immutep retains commercial rights to efti with freedom to operate.